

# WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 31 janvier 2025 09:47

## LABORATORY INFORMATION

|   |   |
|---|---|
| <b>*Name of disease (or topic) for which you are a designated WOA Reference Laboratory:</b> | Avian chlamydiosis                                  |
| <b>*Address of laboratory:</b>  | 22 rue Pierre et Marie Curie / Maisons-Alfort 94706 |
| <b>*Tel:</b>  | +330149771350                                       |
| <b>*E-mail address:</b>   | karine.laroucau@anses.fr                            |
| <b>Website:</b>   |   |
| <b>*Name (including Title) of Head of Laboratory (Responsible Official):</b>                | Dr Zientara Stéphan                                 |
| <b>*Name (including Title and Position) of WOA Reference Expert:</b>                        | Dr Laroucau Karine                                  |
| <b>*Which of the following defines your laboratory? Check all that apply:</b>               | Governmental  |

## TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test                    | Indicated in WOA Manual (Yes/No) | Total number of test performed last year |                 |
|------------------------------------|----------------------------------|--|-----------------|
| Indirect diagnostic tests          |                                  | Nationally                               | Internationally |
| Direct diagnostic tests            |                                  | Nationally                               | Internationally |
| real-time PCR Chlamydiaceae family | Yes                              | 608                                      | 139             |
| real-time PCR Chlamydia psittaci   | Yes                              | 86                                       | 3               |
| real-time PCR Chlamydia abortus    | No                               | 25                                       | 3               |
|                                    |                                  |  |                 |

**Karine Laroucau - - FRANCE**

|                                    |    |    |   |
|------------------------------------|----|----|---|
| real-time PCR Chlamydia gallinacea | No | 34 | 3 |
| real-time PCR Chlamydia avium      | No | 42 | 3 |

## TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

| Type of reagent available          | Related diagnostic test | Produced/ provide | Amount supplied nationally (ml, mg) | Amount supplied internationally (ml, mg) | No. of recipient WOA?H Member Countries | Country of recipients |
|------------------------------------|-------------------------|-------------------|-------------------------------------|--|---|-----------------------|
| DNA of Chlamydia reference strains | real-time PCR           | produced          | 1 x 100 µL                          | 0  | 1                                       | FRANCE,               |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

| Name of the new test or diagnostic method developed  | Description and References (Publication, website, etc.)  |
|--|--|
| High-throughput microfluidic real-time PCR for the detection of a wide range of avian infectious agents, including Chlamydiaceae | Microfluidic high-throughput real-time polymerase chain reaction (Htrt PCR) has emerged as a promising first-line tool for detecting a wide range of infectious agents and addressing disease ecology questions. This technology enables the simultaneous screening of large batches of samples by real-time PCR for up to dozens of targeted infectious agents (e.g., screening 28 infectious agents in 45 samples simultaneously). (Manuscript submitted for publication.) |

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

| Name of the WOA Member Country receiving a technical consultancy | Purpose   | How the advice was provided           |
|--|---|---------------------------------------|
| BRAZIL   | Consultancy and training on Chlamydiae detection and typing in various bird species | Email support, training and analysis. |

## TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

Yes

| Title of the study                               | Duration | Purpose of the study  | Partners (Institutions)                                     | WOA Member Countries involved other than your country |
|--|----------|---|---|---|
| Prevalence of Chlamydiae in wild birds in Brazil | 1 year   | To study the prevalence and strain diversity of Chlamydia in birds. | University of Sao Paulo                                     | BRAZIL  |
| Characterisation of Chlamydia strains            | 2 years  | Molecular characterisation of Chlamydia strains from flamingos      | Robert Koch Institute<br>Friedrich Schiller University Jena | GERMANY   |

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOA?

No

## TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

4

Marti H, Shima K, Boutin S, Rupp J, Clarke IN, Laroucau K, Borel N. Zoonotic and other veterinary chlamydiae - an update, the role of the plasmid and plasmid-mediated transformation. *Pathog Dis.* 2024 Feb 7;82:ftae030. doi: 10.1093/femspd/ftae030.

Vorimore F, Aaziz R, Al Qaysi L, Wernery U, Borel N, Sachse K, Laroucau K. Detection of a novel genotype of *Chlamydia buteonis* in falcons from the Emirates. *Vet Microbiol.* 2024 Apr;291: 110027. doi: 10.1016/j.vetmic.2024.110027.

## Karine Laroucau - - FRANCE

Herrmann B, Aaziz R, Kaden R, Riedel HM, Spörndly-Nees E, Sandelin LL, Laroucau K. SNP-based high-resolution typing of *Chlamydia psittaci* from humans and wild birds in Sweden: circulation of the Mat116 genotype reveals the transmission mode to humans. *Microbes Infect.* 2024 Mar-Apr;26(3):105251. doi: 10.1016/j.micinf.2023.105251.

Le Gall-Ladevèze C, Vollot B, Lèbre L, Aaziz R, Laroucau K, Guérin JL, Cappelle J, Le Loc'h G. Limited transmission of avian influenza viruses, avulaviruses, coronaviruses and *Chlamydia* sp. at the interface between wild birds and a free-range duck farm", *Veterinary Research*: (in press)

### b) International conferences:

2

Laroucau K. Recent advances in veterinary research on Chlamydiaceae, Chlam Health Meeting, Ascona (Switzerland), 19-23 February 2024. Invited speaker

Bralet T, Aaziz R, Lejeune M, Clessin A, Galon C, Gamble A, Tornos J Moutailler S, Laroucau K, Boulinier T. Detection of a panel of infectious agents in seabird populations of southernocean islands using a multiple microfluidic PCR tool. 7th International Albatross and Petrel Conference, Coimbra (Portugal), 4-9 September 2024.

### c) National conferences:

1

Bralet T, Aaziz R, Lejeune M, Clessin A, Galon C, Gamble A, Tornos J Moutailler S, Laroucau K, Boulinier T. Detection of a panel of infectious agents in seabird populations of southernocean islands using a multiple microfluidic PCR tool. Journées Scientifiques et Doctorales de l'Anses, Maisons-Alfort (France), 2-3 October 2024.

### d) Other (Provide website address or link to appropriate information):

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 0

d) Internships (>1 month) 1

| Type of technical training provided (a, b, c or d) | Country of origin of the expert(s) provided with training | No. participants from the corresponding country |
|--|---|---|
| D  | BRAZIL  | 1   |

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

**Karine Laroucau - - FRANCE**

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |                              |
|-----------------------------------|---|------------------------------|
| ISO17025                          | Accreditation bu COFRAC                 | Attestation 1-7341_Rév01.pdf |

19. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|--|--------------------|
| real-time PCR Chlamydiaceae                  | COFRAC             |

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Risk assessment for Chlamydia agents is conducted with regular updates. Appropriate risk control measures, including biosecurity and biosafety protocols, are in place. A biological safety officer has been appointed to oversee compliance. Additionally, the Level-3 laboratory undergoes regular official inspections by national authorities to ensure safety and regulatory adherence regarding highly infectious pathogens.

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

## TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOA Reference Laboratories designated for the same pathogen?

Yes

| NETWORK/DISEASE    | ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC) | NO. PARTICIPANTS | PARTICIPATING WOA REF. LABS                                    |
|--------------------|---|------------------|--|
| Avian chlamydiosis | participant   | 2                | WOA ref lab from Germany (FLI) WOA ref lab from France (Anses) |

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

| Purpose of the proficiency test: | Role of your Reference Laboratory (organiser/ participant) | No. participating Laboratories | Participating WOA Ref. Labs/ organising WOA Ref Lab |
|----------------------------------|--|--------------------------------|---|
| Assessment of the technical      |  |                                |   |

**Karine Laroucau - - FRANCE**

|   |   |                                   |  |
|---|---|-----------------------------------|--|
| competence of laboratories in detecting <i>Chlamydia psittaci</i> , <i>C. abortus</i> , and <i>C. pecorum</i> genomic DNA by real-time PCR. | WOAH ref lab from France (Anses) as participant | 2 WOAH ref Labs and 37 other Labs | WOAH ref lab from Germany (FLI) as organiser |
|---|---|-----------------------------------|--|

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

| Title of the project or contract            | Scope  | Name(s) of relevant WOAH Reference Laboratories                  |
|---|--|--|
| C. avium diversity and pathogenicity        | Diversity and pathogenicity of <i>C. avium</i>   | WOAH ref lab from Germany (FLI) WOAH ref lab from France (Anses) |
| Improvement of <i>C. gallinacea</i> culture | Compare different protocols (cell lines, incubation temperature, ...) for the cultivation of <i>C. gallinacea</i> on cell lines. | WOAH ref lab from France (Anses) WOAH ref lab from Germany (FLI) |

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen during the past 2 years?

No

x

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

No

29. Additional comments regarding your report:

Yes

*Revision of the Avian Chlamydiosis Code Chapter 10.1 and the revision of the Avian Chlamydiosis Chapter (3.3.1) of the WOAH Terrestrial Manual.*